Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitors Combined With Venetoclax+CAG Regimens in R/R T-ALL
NCT07541755Phase 3Active, not recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- May 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of venetoclax in T-cell acute lymphoblastic leukemia (T-ALL), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Morphologic Complete Remission with Incomplete Hematologic Recovery at 6 weeks. Started May 2025; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
T-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT07541755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07541755.